IRD

#3307
Opus Genetics, Inc. - Common Stock
3.6 9 USD
-0.04%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
3.69
3.69
Intervallo Annuale
2.82
5.81
Variazione giornaliera
-4.16%
Variazione Mensile
-4.16%
Variazione di 6 mesi
-9.56%
Variazione Annuale
-0.81%
Chiusura Precedente
3.8 5
Open
3.6 9
Minimo
3.6 9
Massimo
3.6 9
Volume
59
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Opus Genetics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Opus Genetics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Opus Genetics, Inc. quarterly report, Q1 FY2026
10-Q

Opus Genetics, Inc. current report, Q2 FY2025

Full document

Business Context and Reporting Period

Opus Genetics, Inc. (IRD) filed a Form 8-K on April 2, 2025, reporting the termination of a material definitive agreement. The company is a Delaware corporation with principal executive offices in Durham, NC.

Key Financial Metrics and Agreement Details

  • Agreement Terminated: Purchase Agreement dated August 10, 2023, with Lincoln Park Capital Fund, LLC.
  • Total Facility Size: Up to $50 million in common stock.
  • Shares Issued Prior to Termination: 1,700,000 shares.
  • Net Proceeds Received: Approximately $5.2 million.
  • Remaining Capacity at Termination: Approximately $44.8 million.
  • Effective Termination Date: April 3, 2025.

Note: This filing does not provide current revenue, profit, cash flow, margin, or debt metrics for the company.

Material Changes and Rationale

The Company elected to terminate the Purchase Agreement due to existing market dynamics. Management cited the limited value of the facility based on the current market price of the Company's common stock as the primary driver for this decision.

Outlook, Risks, and Surviving Provisions

  • Surviving Obligations: Representations, warranties, indemnification obligations, and certain covenants survive termination.
  • Registration Rights: Obligations under the Registration Rights Agreement survive for 90 days following the April 3, 2025 termination date to facilitate the registration of shares previously issued to Lincoln Park.
  • Future Capital Access: The termination removes the option to raise up to $44.8 million through this specific facility, potentially limiting near-term capital flexibility via this channel.

Key Facts for Investor Verification

  • Verify the current market price of Opus Genetics common stock to understand the "limited value" rationale cited by management.
  • Confirm the status of the 90-day registration rights period for the 1.7 million shares previously issued.
  • Assess the company's alternative capital raising strategies given the loss of the $44.8 million remaining facility capacity.
  • Review recent 10-Q or 10-K filings for the most recent liquidity and cash position data, as this 8-K does not contain updated financial statements.